Drug Profile
Recombinant idursulfase - JCR Pharmaceuticals/GlaxoSmithKline
Alternative Names: GSK-2788723; iduronate-2-sulfatase; JR-032; recombinant idursulfase; recombinant-iduronate-2-sulfataseLatest Information Update: 09 Oct 2021
Price :
$50
*
At a glance
- Originator JCR Pharmaceuticals
- Developer GlaxoSmithKline KK; JCR Pharmaceuticals
- Class Iduronate sulfatases; Recombinant proteins
- Mechanism of Action Iduronate sulfatase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Mucopolysaccharidosis II
Most Recent Events
- 28 May 2020 No recent reports of development identified for preclinical development in Mucopolysaccharidosis-II in Japan (Parenteral)
- 22 May 2018 Preclinical development is ongoing for Mucopolysaccharidosis-II in Japan (Parenteral) (JCR Pharmaceutical pipeline, May 2018)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Mucopolysaccharidosis-II in Japan (Parenteral)